Glaxosmithkline plc (GSK) pledged $2.1 billion up front and as much as $1.2 billion in development milestone payments to take over privately held Affinivax Inc. and bring aboard the phase II-stage, next-generation, 24-valent pneumococcal vaccine candidate, AFX-3772。总部位于伦敦的GSK在今年第三季度完成交易后,以21亿美元的价格购买了马萨诸塞州剑桥市的Affinivax的所有流通股,如果某些儿科发展目标是某些儿科发展目标,则支付两项潜在的里程碑式支付6亿美元到达。
Futura Medical Plc已与Counter(OTC)分销商Cooper Consumer Health SAS签署了一项独家许可协议,以在英国和欧洲商业化其基于凝胶的凝胶勃起功能障碍(ED)MED3000。根据协议的条款,库珀将根据欧盟竞争法,向Futura支付未公开的价格,以制造和提供该产品五年。